Skip to content
Study details
Enrolling now

Antiviral Clinical Trial for Long Covid-19

Icahn School of Medicine at Mount Sinai
NCT IDNCT06511063ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

90

Study length

about 1.3 years

Ages

18+

Locations

1 site in NY

What this study is about

This trial is testing if two repurposed HIV antivirals can reduce symptom burden in adults with Long Covid compared to placebo. Participants will be randomly assigned to receive antivirals, Truvada (tenofovir disoproxil/emtricitabine), Selzentry, or a placebo taken daily for 90 days.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Placebo
  • 2.Take Selzentry
  • 3.Take tenofovir disoproxil/emtricitabine

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Oral

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

emtricitabine, tenofovir disoproxil

Drug routes

oral (Oral Capsule)

Endpoints

Primary: EuroQol 5-Dimension 5-Level (EQ-5D-5L) Visual Analogue Scale

Secondary: Composite Autonomic Symptom Score 31(COMPASS-31), Fatigue Severity Scale (FSS), Fatigue Visual Analogue Scale (F-VAS), General Symptom Questionnaire (GSQ-30), Generalized Anxiety Disorder (GAD-7), Neuro-QoL™ v2.0 Cognitive Function-Short Form, Pain Visual Analogue Scale (P-VAS), Patient Health Questionnaire (PHQ-9)